

Reprinted from

JOURNAL of CHROMATOGRAPHY B

Journal of Chromatography B, 710 (1998) 121–128

High-performance liquid chromatographic determination of
furosemide in plasma and urine and its use in bioavailability
studies

Hisham S. Abou-Auda, Mohammad J. Al-Yamani, Abdelrehim M. Morad,
Saleh A. Bawazir, Saeed Z. Khan, Khalil I. Al-Khamis*

College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh-11451, Saudi Arabia

Received 3 October 1997; received in revised form 16 January 1998; accepted 27 January 1998



JOURNAL OF CHROMATOGRAPHY B

BIOMEDICAL SCIENCES AND APPLICATIONS



ELSEVIER

Scope. The *Journal of Chromatography B* addresses developments in and applications of separation science related to drugs and other pharmacologically active compounds, and to research in biomedical sciences. The areas considered include: clinical diagnosis or alterations during medical treatment; screening and profiling of body fluids or tissues related to the analysis of active substances and to metabolic disorders; drug level monitoring; pharmacodynamic, pharmacokinetic and pharmacogenetic studies; analysis of toxicants in biological and food matrices; pharmaceutical analysis; forensic medicine; veterinary medicine; occupational medicine. Techniques covered include the various facets of chromatography, electrochromatography, electrophoresis and related methods, as well as hyphenated techniques, applied mass spectrometry and immuno-affinity separation techniques.

Submission of Papers. The preferred medium of submission is on disk with accompanying manuscript. Manuscripts (in English; four copies are required) should be submitted to: Editorial Office of *Journal of Chromatography B*, P.O. Box 681, 1000 AR Amsterdam, Netherlands. Review articles are invited or proposed in writing to the Editors who welcome suggestions for subjects. An outline of the proposed review should first be forwarded to the Editors for preliminary discussion prior to preparation. Submission of an article is understood to imply that the article is original and unpublished and is not being considered for publication elsewhere. For copyright regulations, see below.

Subscription information. For 1998 Vols. 702-716 of *Journal of Chromatography B* (ISSN 0378-4347) are scheduled for publication. Subscription prices for *Journal of Chromatography A + B* (combined), or for section *A* or *B* are available upon request from the publisher. Subscriptions are accepted on a prepaid basis only and are entered on a calendar year basis. Issues are sent by surface mail except to the following countries where air delivery via SAL is ensured: Argentina, Australia, Brazil, Canada, China, Hong Kong, India, Israel, Japan, Malaysia, Mexico, New Zealand, Pakistan, Singapore, South Africa, South Korea, Taiwan, Thailand, USA. For all other countries airmail rates are available upon request. Claims for missing issues must be made within six months of our publication (mailing) date.

Orders, claims, and product enquiries: please contact the Customer Support Department at the Regional Sales Office nearest you:

New York
Elsevier Science
P.O. Box 945
New York, NY 10159-0945
USA
Tel. (+1)212-633-3730
[Toll free number for North
American customers:
1-888-4ES-INFO (437-4636)]
Fax (+1)212-633-3680
e-mail usinfo-f@elsevier.com

Amsterdam
Elsevier Science
P.O. Box 211
1000 AE Amsterdam
The Netherlands
Tel. (+31)20-4853757
Fax (+31)20-4853432
e-mail nlinfo-f@elsevier.nl

Tokyo
Elsevier Science
9-15 Higashi-Azabu 1-chome
Minato-ku, Tokyo 106
Japan
Tel. (+81)3-5561-5033
Fax (+81)3-5561-5047
e-mail info@elsevier.co.jp

Singapore
Elsevier Science
No. 1 Temasek Avenue
#17-01 Millenia Tower
Singapore 039192
Tel. (+65)434-3727
Fax (+65)337-2230
e-mail asiainfo@elsevier.com.sg

Enquiries concerning manuscripts and proofs: questions arising after acceptance of the manuscript, especially those relating to proofs, should be directed to: Elsevier Science B.V., *Journal of Chromatography*, Tel. (+31-20)4852793; Fax (+31-20) 4852775; E-mail: k.crabbendam@elsevier.nl

For information on editorial matters (including submission, reviews and revision of manuscripts) please contact: Editorial Office, *Journal of Chromatography*, P.O. Box 681, 1000 AR Amsterdam, The Netherlands; Tel.: (+31-20) 4852794; Fax: (+31-20) 4852304; E-mail: chrom-ee@elsevier.nl

PUBLICATION SCHEDULE FOR THE 1998 SUBSCRIPTION

Journal of Chromatography B

Nov.-Dec. '97	Jan.-Mar.	Apr.	May	June	
702-704	705/1+2 706/1+2	707/1+2 708/1+2	709/1 709/2	710/1+2 711/1+2	The publication schedule for further issues will be published later.



ContentsDirect, the *free* e-mail alerting service, delivers the table of contents for this journal directly to your PC, prior to publication. The quickest way to register for **Contents Direct** is via the Internet at: <http://www.elsevier.nl/locate/ContentsDirect>. If you don't have access to the Internet you can register for this service by sending an e-mail message to cdsubs@elsevier.co.uk - specifying the title of the publication you wish to register for.

Abstract

A sensitive, for the determi with acceptabl to 2.00 µg/ml eluted through acetonitrile (6% plasma and fro to 6.81% for u to be 5 ng/ml furosemide in the routine mc rights reserved

Keywords: Furo

1. Introduction

Furosemide the treatment cardiac, chro congestive h liver [5]. Th pharmacokin attributed to

*Corresponding

0378-4347/98/\$ PII: S0378-4



ELSEVIER

Journal of Chromatography B, 710 (1998) 121–128

JOURNAL OF
CHROMATOGRAPHY B

High-performance liquid chromatographic determination of furosemide in plasma and urine and its use in bioavailability studies

Hisham S. Abou-Auda, Mohammad J. Al-Yamani, Abdelrehim M. Morad,
Saleh A. Bawazir, Saeed Z. Khan, Khalil I. Al-Khamis*

College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh-11451, Saudi Arabia

Received 3 October 1997; received in revised form 16 January 1998; accepted 27 January 1998

Abstract

A sensitive, selective and efficient reversed-phase high-performance liquid chromatographic (HPLC) method is reported for the determination of furosemide in human plasma and urine. The method has a sensitivity limit of 5 ng/ml in plasma, with acceptable within- and between-day reproducibilities and good linearity ($r^2 > 0.99$) over a concentration range from 0.05 to 2.00 $\mu\text{g/ml}$. The one-step extract of furosemide and the internal standard (warfarin) from acidified plasma or urine was eluted through a $\mu\text{Bondapak C}_{18}$ column with a mobile phase composed of 0.01 M potassium dihydrogenphosphate and acetonitrile (62:38, v/v) adjusted to pH 3.0. Within-day coefficients of variation (C.V.s) ranged from 1.08 to 8.63% for plasma and from 2.52 to 3.10% for urine, whereas between-day C.V.s ranged from 4.25 to 10.77% for plasma and from 5.15 to 6.81% for urine at three different concentrations. The minimum quantifiable concentration of furosemide was determined to be 5 ng/ml. The HPLC method described has the capability of rapid and reproducible measurement of low levels of furosemide in small amounts of plasma and urine. This method was utilized in bioavailability/pharmacokinetic studies for the routine monitoring of furosemide levels in adults, children and neonate patients. © 1998 Elsevier Science B.V. All rights reserved.

Keywords: Furosemide

1. Introduction

Furosemide is a potent and widely used diuretic in the treatment of edematous states associated with cardiac, chronic renal failure [1,2], hypertension, congestive heart failure [3,4] and cirrhosis of the liver [5]. The large degree of variability in the pharmacokinetic behavior of furosemide can be attributed to the differences in organ function, the

types of patients treated with furosemide and from differences within- and between subjects and study protocols [6]. The site of action of furosemide is believed to be at the lumen surfaces [7]. Because it is highly protein bound [8], access of furosemide to this site occurs through active secretion into the tubule lumen via the nonspecific organic acid of the proximal tubule [9].

The bioavailability of furosemide from oral dosage forms is highly variable. Drug information sources generally report values in the 60 to 65% range for

*Corresponding author.

the extent of absorption [10,11]. The half life reported for furosemide in healthy subjects generally falls in the range of 30 to 120 min, and is influenced by the underlying disease process, while its half-life reported in patients with congestive heart failure is in the range of 50–327 min (mean=122 min) [12].

Several analytical methods for the determination of furosemide in plasma and urine have been reported, including spectrophotometric [12–14] and spectrofluorometric methods [15–18]. These methods suffer from a lack of sensitivity and selectivity and are not suitable for routine determination of furosemide. Although gas chromatographic methods [19,20] are more sensitive, they require a laborious extraction procedure and derivatization of furosemide prior to analysis. Therefore, the analysis time may exceed 1 h per sample. Four methods were reported that allow the determination of furosemide in plasma using thin-layer chromatography [21–24]. These methods require complicated preparative steps before quantitation of the drug can be carried out.

A variety of high-performance liquid chromatography (HPLC) techniques [25–44] were recently developed. Some of these [25–27,29,30,38] required 1–2 ml of plasma. Other methods required lengthy sample extraction and have very long elution times for the drug and the internal standard [29,31–33,36]. Farthing et al. [41] used an external standard and solid-phase extraction, while Reeuwijk et al. [42] used the lengthy and tedious technique of reversed-phase ion pair chromatography. On the other hand, Saugy et al. [43] used gas chromatography–mass spectrometry with different types of ionization to confirm the occurrence of furosemide after permethylation of the extract eluted by HPLC. Most of the HPLC methods have not achieved the complete separation of furosemide from endogenous substances with a minimum detectable concentration of less than 20 ng/ml, which would allow their application to the measurement of low furosemide concentrations in biological fluids. Most of the previously reported methods published the precision of the calibration data but usually omitted the accuracy for concentrations at the lower end of the concentration range found in pharmacokinetic and bioavailability/bioequivalence studies. Furthermore, the minimum quantifiable concentrations are rarely reported. A summary report of analytical methods validation [45], sponsored by the U.S. Food and Drug Adminis-

tration, the American Association of Pharmaceutical Scientists and other agencies, outlined the acceptable standards for documenting and validating analytical methods and procedures to yield reliable results in bioavailability, bioequivalence and pharmacokinetic studies that can be satisfactorily interpreted. Most of the HPLC assays for furosemide analysis do not meet all the criteria suggested by the summary report. Interference from commonly administered drugs is also not uncommon in those methods [29,30,33]. Potential interference from the major furosemide metabolite, furosemide glucuronide, and the hydrolytic product 4-chloro-5-sulfamoyl anthranilic acid (CSA) was also not reported for the majority of these methods. These disadvantages may limit their use in the therapeutic drug monitoring of furosemide levels in patients as well as in pharmacokinetic bioequivalence studies of furosemide.

In this paper, we report a rapid, sensitive and selective reversed-phase HPLC assay that meets the acceptable criteria for analytical method validation and that is suitable for the processing of a large number of furosemide samples.

2. Experimental

2.1. Chemicals and reagents

All chemicals and reagents were of analytical grade and were used as received. The organic solvents used for extraction and in the mobile phase were of HPLC grade (BDH, Poole, UK). Furosemide was obtained from Dumex and the internal standard, warfarin, was obtained from Sigma (St. Louis, MO, USA).

2.2. Apparatus

The HPLC system consisted of a single-piston solvent delivery pump, Model 501; an automatic injector, Model WISP 710B; a scanning fluorescence detector, Model 470, and a data module integrator, Model 746. Analytical separation was accomplished using a μ Bondapak C_{18} reversed-phase column (15 cm \times 3.9 mm I.D., 10 μ m particle size) for plasma and a resolve spherical C_{18} column (15 cm \times 3.9 mm I.D., 5 μ m particle size) for urine. All of the above

were su
USA).

2.3. CH

A m
dihydro
phosph
was fi
(Millip
flow-ra
column
wavele
separat

2.4. SI

The
 μ g/ml
mg of
methan
pared
volum
dilutin
solitic
nol. B
standa
coveri
stored
three

Cal
ml fo
were
the st
of dr
speci
intern
tube
accou
extra
ysis
prese

2.5.

2.5.1

Tc
speci

were supplied by Waters Associates (Milford, MA, USA).

2.3. Chromatographic conditions

A mobile phase containing 0.01 M potassium dihydrogen (62:38, v/v) adjusted to pH 3.0 with phosphoric acid (1:3, v/v) was used. The mixture was filtered through a 0.22- μ m membrane filter (Millipore, Bedford, MA, USA) under vacuum. The flow-rate was 1.5 ml/min. The eluents from the column were detected at excitation and emission wavelengths of 225 and 389 nm, respectively. The separation was carried out at ambient temperature.

2.4. Standard solutions

The standard stock solution of furosemide (200 μ g/ml) was prepared by dissolving and diluting 10 mg of furosemide in a 50-ml volumetric flask with methanol. The internal standard solution was prepared by dissolving 500 mg of warfarin in a 50-ml volumetric flask (10 mg/ml) using methanol as the diluting solvent. For plasma, the internal standard solution was further diluted by ten-folds with methanol. Both the standard stock solution and the internal standard solution were protected from light by covering them with aluminum foil and they were stored at 4°C. Both solutions were stable for at least three months.

Calibration curves, ranging from 0.05 to 2.00 μ g/ml for plasma and 0.50 to 50.00 μ g/ml for urine, were constructed by adding appropriate volumes of the stock solutions of furosemide to 0.5 ml aliquots of drug-free plasma and 200 μ l of drug-free urine specimens in each run of the assay. The volumes of internal standard (10 mg/ml warfarin) added to each tube were 30 μ l for plasma and 40 μ l for urine, to account for any variability in recovery through extraction. A weighted least squares regression analysis was the best-fit regression line. Data were presented as mean \pm S.D.

2.5. Analytical procedure

2.5.1. Plasma

To a 10-ml stoppered glass tube, 0.5 ml of plasma specimen, 30 μ l of internal standard (10 mg/ml

warfarin), 50 μ l of 6 M hydrochloric acid and 3 ml of HPLC-grade diethyl ether were added. The tube was closed tightly and vortex-mixed for 30 s and centrifuged at a speed of 2000 g for 10 min. The ether layer was quantitatively transferred to another clean centrifuge tube. On a water bath adjusted at 45°C, the ether was allowed to evaporate under a stream of nitrogen gas. The residue was reconstituted in 100 μ l of methanol and a 20- μ l aliquot was injected onto the column.

2.5.2. Urine

To a 10-ml stoppered glass tube, 200 μ l of urine, 20 μ l of 6 M hydrochloric acid, 40 μ l of the internal standard solution (10 mg/ml warfarin) and 8 ml of HPLC-grade diethyl ether were added. The contents of the tube were vortex-mixed for 30 s. The ether layer was quantitatively transferred to another clean centrifuge tube, and evaporated to dryness on a water bath adjusted to 45°C under a stream of nitrogen gas. The residue was reconstituted in 100 μ l of mobile phase and a 20- μ l aliquot of the solution was injected onto the column.

2.5.3. Clinical study

Three formulations of furosemide were administered to six healthy male volunteers in a crossover design experiment, separated by a one week washout period. The volunteers fasted overnight for at least 10 h before the administration of drug (40 mg tablet) and they continued fasting until 3 h post dose. The participants did not take any other medication for at least two weeks prior to and during the day of the study. Venous blood samples were drawn into heparinized tubes before drug administration and at 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10.0 and 12.0 h after the drug was given. All blood samples were taken via an indwelling catheter. The blood samples were centrifuged at 1100 g for 15 min and the plasma samples were frozen at -20°C pending analysis.

During each study day, urine was collected immediately before drug administration and at the following intervals: 0–1, 1–2, 2–3, 3–4, 4–5, 5–6, 6–8, 8–12 and 12–24 h after drug administration. Urine volumes were recorded and an aliquot was frozen at -20°C until it was assayed.

3. Results and discussion

The determination of drug concentrations in plasma and urine and pharmacokinetic parameters in bioavailability/bioequivalence studies require both precise and accurate data. Several published furosemide assays failed to report the possible interferences from furosemide metabolites and degradation products. This lack of specificity may result in an overestimation of actual concentrations, leading to erroneous bioavailability/bioequivalence decisions. The composition and pH of the mobile phase used in the present assay provided good separation of furosemide and warfarin and gave sharp peaks with no interferences from endogenous components in either plasma or urine. Fig. 1 shows representative chromatograms of blank plasma and a subject's plasma sample obtained by the above described method. The chromatograms showed excellent resolution between furosemide and the internal standard, appearing at 3.0 and 9.0 min, respectively. No interference was observed during the chromatographic run of the plasma and the urine sample in the area where furosemide or the internal standard peak appears. The retention time of the hydrolytic product CSA is less than 2 min and, thus, will not interfere with furosemide or the internal standard. This method allows the determination of the concentration of furosemide within 10 min.

Quantitation of furosemide in plasma and urine samples was carried out by determining the slope of the calibration curve, constructed using the peak-area ratio for furosemide and the internal standard (warfarin), obtained for the calibration standards. The calibration curves of furosemide was typically described by $Y=0.0005(\pm 0.017)+1.157(\pm 0.119)X$, ($r^2=0.994$; $n=10$), where Y corresponds to the peak-area ratio of furosemide to the internal standard and X to the concentration of furosemide added over a concentration range of 0.5 to 50 $\mu\text{g/ml}$. The linear least-squares equation was $Y=0.012(\pm 0.086)+0.042(\pm 0.002)X$, $r^2=0.998$; $n=9$.

Standard curves for furosemide were constructed on different days to determine the variability of the slopes and intercepts. The results showed little day-to-day variability of slopes and intercepts and gave acceptable linearity ($r>0.996$) over the plasma and urine concentration ranges studied. The coefficient of




Fig. 1. Liquid chromatograms of: (I) Plasma samples, (A) blank plasma, (B) blank plasma spiked with the internal standard, (C) plasma extract from a healthy subject following oral administration of a furosemide tablet (furosemide concentration= $0.60 \mu\text{g/ml}$). (II) Urine samples, (A) blank urine, (B) blank urine spiked with the internal standard, (C) urine extract from a healthy subject following oral administration of a furosemide tablet (furosemide concentration= $8.03 \mu\text{g/ml}$); W=warfarin (internal standard).

variation for the slopes was 10.32% for the plasma assay and 5.14% for the urine assay.

To evaluate the precision of the method, the drug-free plasma and the urine were spiked with three different known concentrations (low, medium, high) of drug. The spiked samples were analyzed both on the same day and on different days to determine the variability. The within-day precision showed a coefficient of variation (C.V.) of 1.08 to 8.63% and a

Table 1
Within-day and

Added
concentration
($\mu\text{g/ml}$)

0.08

0.4

1.8

^a Mean value n

^b Day-to-day r

between-day

(Table 1). F

C.V. of 2.52

5.15 to 6.81

concentratio

ng/ml. How

Table 2

Within-day and

Added

concentration

($\mu\text{g/ml}$)

precision

(%)

7.50

25

45

^aMean value n

^bDay-to-day re

Table 3

Analytical rec

Concentration

($\mu\text{g/ml}$)

0.080

0.40

1.80

^a Eight replica

Table 1
Within-day and day-to-day accuracy and precision of furosemide in plasma

Added concentration (µg/ml)	Within-day ^a			Day-to-day ^b		
	Measured concentration (µg/ml)	Accuracy (%)	Precision (%)	Measured concentration (µg/ml)	Accuracy (%)	Precision (%)
0.08	0.077±0.0066 n=11	-3.75	8.63	0.084±0.009 n=11	5.0	10.77
0.4	0.368±0.0054 n=9	-8.0	1.47	0.42±0.027 n=10	5.5	6.40
1.8	1.57±0.017 n=9	-12.78	1.08	1.79±0.76 n=12	-0.56	4.25

^a Mean value represents different plasma samples for each concentration.

^b Day-to-day reproducibility was determined from different runs over a six-week period for the three concentrations.

between-day precision of 4.25 to 10.77% for plasma (Table 1). For urine, within-day precision showed a C.V. of 2.52 to 3.10% and a between-day precision of 5.15 to 6.81% (Table 2). The minimum quantifiable concentration of furosemide was determined to be 5 ng/ml. However, the minimum detectable concen-

tration was in the order of 2–3 ng/ml using a signal-to-noise ratio of three.

The absolute and relative recoveries of furosemide in plasma and urine were determined at three different concentration levels by comparing extracted versus unextracted samples. Tables 3 and 4 show the

Table 2
Within-day and day-to-day accuracy and precision of furosemide in urine

Added concentration (µg/ml)	Within-day ^a			Day-to-day ^b		
	Measured concentration (%)	Accuracy (µg/ml)	Precision (%)	Measured concentration (%)	Accuracy (µg/ml)	Precision (%)
7.50	8.07±0.25 n=10	7.60	3.10	7.80±0.44 n=12	4.00	5.64
25	25.36±0.71 n=12	1.44	2.80	26.04±1.34 n=12	4.16	5.15
45	43.70±1.10 n=10	-2.89	2.52	46.27±3.15 n=11	2.84	6.81

^a Mean value represents different plasma samples for each concentration.

^b Day-to-day reproducibility was determined from different runs over a six-week period for the three concentrations.

Table 3
Analytical recovery of furosemide from plasma^a

Concentration (µg/ml)	Mean peak area ratio		Absolute recovery (%)	Relative recovery (%)	
	Aqueous	Plasma		Mean	Range
0.080	0.09	0.064	71.11	95.75	82.69–109.0
0.40	0.405	0.39	96.30	91.9	89.55–93.92
1.80	2.038	2.098	102.91	87.31	85.96–88.85

^a Eight replicate injections of each concentration.

Table 4
Analytical recovery of furosemide from urine^a

Concentration (µg/ml)	Mean peak area ratio		Absolute recovery (%)	Relative recovery (%)	
	Aqueous	Plasma		Mean	Range
7.5	0.292	0.313	107.19	107.60	01.87-111.87
25	1.078	1.005	93.23	101.4	98.08-106.20
45	1.947	1.750	89.88	87.31	93.60-101.84

^a Eight replicate injections of each concentration.

recovery of furosemide in plasma and urine. The data obtained showed satisfactory recovery for furosemide in plasma as well as in urine and the extraction provided adequate sensitivity to process the samples.

To determine the specificity of the assay, blank plasma samples, collected from healthy adult male volunteers, were analyzed using the reported procedure. Chromatograms were inspected for the presence of interfering peaks. In addition, other commonly administered drugs were tested for their possible interference under the same chromatographic conditions. Table 5 lists the retention times for some of the frequently coadministered drugs. In addition, no interfering peaks were observed for furosemide's metabolite or its hydrolytic product.

Blank plasma samples were spiked with known amounts of furosemide at three different concen-

Table 5
Retention times for commonly used drugs using the current method

Drug	Retention time (min)
Carbamazepine	N.D.
Cimetidine	N.D.
Diazepam	N.D.
Disopyramide	N.D.
Fluvoxamine	N.D.
Meclofenamate	N.D.
Metoclopramide	N.D.
Phenobarbital	N.D.
Phenylbutazone	N.D.
Phenytoin	N.D.
Quinidine	1.80
Ranitidine	N.D.
Sulfamethoxazole	2.00
Theophylline	N.D.
Trimethoprim	N.D.

N.D., not detected.

Table 6
Pharmacokinetic parameters

Parameter	Value
AUC _{0-∞} (ng/ml·h)	107.60
C _{max} (ng/ml)	101.4
T _{max} (h)	93.60-101.84
K _{el} (h ⁻¹)	
t _{1/2} (h)	
AU ₀₋₂₄ (mg)	
AUC _{0-∞} , area under the curve	
C _{max} , peak concentration	
T _{max} , time to reach C _{max}	
K _{el} , elimination rate constant	
t _{1/2} , elimination half-life	
AU ₀₋₂₄ , cumulative amount excreted in 24 h	

trations; subsequently the stability of the samples was tested in frozen storage for a 30-day period. The results showed that furosemide was stable in plasma and urine without degradation.

The pharmacokinetic parameters were determined by testing the stability of the formulations at different concentrations and storage conditions.




Fig. 2. Mean furosemide plasma concentrations following oral administration of three tablet formulations of furosemide (40 mg) to six health adult males.

Fig. 3. Me...

Table 6

Pharmacokinetic parameters of furosemide (mean±S.D.) following oral administration (40 mg) of three commercially available formulations to six subjects

Parameter	Brand A	Brand B	Brand C
AUC _{0-∞} (ng·h/ml)	2216.2±146.9	2038.5±466.9	2101.9±642.7
C _{max} (ng/ml)	1058.0±188.1	763.5±242.9	858.2±433.9
T _{max} (h)	1.38±0.54	1.60±0.58	2.2±1.0
K _{el} (h ⁻¹)	0.39±0.06	0.42±0.05	0.42±0.08
t _{1/2} (h)	1.84±0.31	1.66±0.21	1.71±0.41
AU ₀₋₂₄ (mg)	11.18±2.0	11.67±3.57	11.58±2.69

AUC_{0-∞}, area under the plasma concentration–time curve from time 0 to infinity.C_{max}, peak plasma concentration.T_{max}, time of peak concentration.K_{el}, elimination rate constant.t_{1/2}, elimination half life.AU₀₋₂₄, cumulative amount excreted unchanged in urine in 24 h.

trations; 15, 120 and 360 ng/ml, and were subsequently stored in a freezer at -20°C. To determine the stability of the drug in human plasma, the above frozen samples were analyzed over a ten-week period. The results demonstrated that furosemide was stable in the frozen plasma for at least ten weeks without degradation.

The present method was applied to the determination of several pharmacokinetic studies, including testing the bioavailability and bioequivalence of drug formulations. Fig. 2 shows the mean plasma concentration profiles of furosemide after oral administration of a 40-mg tablet from three formulations to

six healthy male volunteers. The calculated pharmacokinetic parameters (AUC_{0-∞}, C_{max}, T_{max}, K_{el} and t_{1/2}) of the three brands are shown in Table 6.

Fig. 3 shows the cumulative amounts of unchanged furosemide in urine.

In conclusion, a rapid, sensitive and selective reversed-phase HPLC analysis of furosemide is reported. The method improves upon previously reported methods for accurate measurement of furosemide concentrations in biological samples and allows the determination of the drug within 10 min. The simplicity of this method for the determination of furosemide in human plasma and urine, coupled




Fig. 3. Mean cumulative amounts of furosemide excreted unchanged in urine following the oral administration of three tablet formulations of furosemide (40 mg) to six healthy adult males.

with its high specificity and sensitivity, provides a particularly suitable analytical method for pharmacokinetic studies and for monitoring the bioavailability/bioequivalence of pharmaceutical formulations.

References

- [1] L.L.B. Laura, D.S. Ronald, *Clin. Pharmacokinet.* 18 (1990) 81.
- [2] F. Cantarovich, C. Galli, L. Benedetti, *Br. Med. J.* 4 (1973) 449.
- [3] H.S. Frazier, H. Yager, *N. Engl. J. Med.* 288 (1973) 246.
- [4] K. Dikshit, J.K. Vyden, J.S. Forrester, K. Chatterjee, R. Parkash, H.J.C. Swan, *N. Engl. J. Med.* 288 (1973) 1087.
- [5] F. Sadikal, *Br. J. Clin. Pract.* 27 (1973) 222.
- [6] P. Chennavasiu, R.A. Johnson, D.C. Brater, *J. Pharmacokinet. Biopharm.* 9 (1981) 623.
- [7] M.B. Burg, L. Stoner, J. Cardinal, N. Green, *Am. J. Physiol.* 225 (1973) 119.
- [8] R. Zini, P. d'Athis, A. Hoareau, J.P. Tillement, *Eur. Clin. Pharmacol.* 10 (1976) 139.
- [9] J.B. Hook, H.E. Williamson, *J. Pharmacol. Exp. Ther.* 149 (1965) 404.
- [10] A.G. Gilman, L.S. Goodman, A. Gilman, *The Pharmacological Basis of Therapeutics*, 8th ed., Macmillan, New York, 1991.
- [11] G.K. McEvoy, G.M. McQuarrie and H.J. DiPietro, *American Hospital Formulary Service Monograph, Furosemide USP (40:28)*, American Hospital Formulary Service, American Society of Hospital Pharmacists, Bethesda, MD, 1987, pp. 1355–1359.
- [12] D.C. Brater, R. Seiwel, S. Anderson, *Kidney Int.* 22 (1982) 171.
- [13] A. Haussler, V.P. Hadjue, *Arzneimittelforsche* 14 (1964) 710.
- [14] F. Andreassen, P. Jacobsen, *Acta Pharmacol. Toxicol.* 35 (1974) 49.
- [15] A.W. Forrey, B. Kimpel, A.D. Blair, R.E. Cutler, *Clin. Chem.* 20 (1974) 152.
- [16] V.P. Hadju, A. Haussler, *Arzneimittelforsche* 14 (1964) 7.
- [17] R.E. Cutler, A.W. Forrey, T.C. Christopher, B.M. Kimpel, *Clin. Pharmacol. Ther.* 15 (1974) 588.
- [18] M.R. Kelly, R.E. Cutler, A.W. Forrey, B. Kimpel, *Clin. Pharmacol. Ther.* 15 (1974) 178.
- [19] B. Lindstrom, M. Molander, *J. Chromatogr.* 101 (1974) 219.
- [20] J. Perez, D.S. Sitar, R.I. Oglivie, *Drug Metab. Dispos.* 7 (1979) 383.
- [21] M. Schafer, H.E. Geissler, E. Mutschler, *J. Chromatogr.* 143 (1977) 636.
- [22] G. Yakatan, D.D. Maness, J. Scholler, W.J. Novick, J.T. Doluisio, *J. Pharm. Sci.* 65 (1976) 1456.
- [23] E. Mikkelsen, F. Andreassen, *Acta Pharmacol. Toxicol.* 41 (1977) 254.
- [24] B. Wesley-Hadzija, A.M. Mattocks, *J. Chromatogr.* 229 (1982) 425.
- [25] A.D. Blair, A.W. Forrey, B.T. Meijssen, R.E. Cutler, *Pharm. Sci.* 64 (1975) 1334.
- [26] B. Lindstrom, *J. Chromatogr.* 100 (1974) 189.
- [27] M.L. MacDougall, D.W. Shoeman, D.L. Azarnoff, *Res. Commun. Pathol. Pharmacol.* 10 (1975) 285.
- [28] H. Roseboom, R.H.A. Sorel, *Anal. Lett.* 16 (1978) 46.
- [29] K. Carr, A. Rane, J. Frolich, *J. Chromatogr.* 145 (1978) 41.
- [30] S.E. Swezey, P.J. Meffin, T.F. Blaschke, *J. Chromatogr.* 17 (1979) 469.
- [31] E.T. Lin, D.E. Smith, L.Z. Benet, B.A. Hoener, *J. Chromatogr.* 163 (1979) 315.
- [32] W. Snedden, J.N. Sharma, P.G. Fernandez, *Ther. Drug Monit.* 4 (1982) 381.
- [33] K. Uchino, S. Isozaki, Y. Saitoh, F. Nakagawa, Z. Tamura, *J. Chromatogr.* 308 (1984) 241.
- [34] R.L. Nation, G.W. Peng, W.L. Chiou, *J. Chromatogr.* 162 (1979) 88.
- [35] R.S. Rapaka, J. Roth, C.T. Viswanathan, T.J. Goehl, V. Prasad, B.E. Cabana, *J. Chromatogr.* 227 (1982) 463.
- [36] A.L.M. Kerremans, Y. Tan, C.A.M. Van Ginneken, W.J. Gribnau, *J. Chromatogr.* 229 (1982) 129.
- [37] L.J. Lovett, G. Nygard, P. Dura, S.K.W. Khalil, *J. Liq. Chromatogr.* 8 (1985) 611.
- [38] M.T. Bauza, C.L. Lesser, J.T. Johnston, R.V. Smith, *J. Pharm. Biomed. Anal.* 3 (1985) 459.
- [39] S.P. Sood, V.I. Green, Z.M. Norton, *Ther. Drug Monit.* 9 (1987) 484.
- [40] T.B. Vree, M. van der Biggelaar Martea, C.P. Verwey van Wissen, *J. Chromatogr. B* 655 (1994) 53.
- [41] D. Farthing, T. Karnes, T.W. Gehr, C. March, I. Fakhry, D.A. Sica, *J. Pharm. Sci.* 81 (1992) 569.
- [42] H.J. Reeuwijk, U.R. Tjaden, J. van der Greef, *J. Chromatogr.* 575 (1992) 269.
- [43] M. Saugy, P. Neuwly, A. Munafo, L. Rvier, *J. Chromatogr.* 564 (1991) 567.
- [44] J.S. Sidhu, B.G. Charles, *J. Chromatogr.* 612 (1993) 161.
- [45] V.P. Shah, K.K. Midha, S. Dighe, I.J. McGilveray, J.P. Skelly, A. Yacobi, T. Layloff, C.T. Viswanathan, C.E. Cook, R.D. McDowall, K.A. Pittman, S. Spector, *Pharm. Res.* 9 (1992) 588.

(Detailed In-
application to
be found on
<http://www.>

Types of C
articles, S
descriptive
reflect the
(one or two
the journal
manuscript
comment
Submission
for public
Authors in
and impr
Higashi-A
Manuscript
manuscript
address
caption (f
be on se
rekeying
For the ini
matching
accordin
important
computer
obtained
Abstract. A
significant
Introductio
stating cl

Experim
appropria

Illustration
paper. E
If structu
author's
publisher
References
on a sep
the titles
press" (j
communi

Vols. 1–
Chromat
should b

Dispatch. I
complet
reprodu
Proofs. On
instances
Reprints. I
contain
For Public

JOURNAL OF CHROMATOGRAPHY B

INFORMATION FOR AUTHORS

(Detailed Instructions to Authors were published in *J. Chromatogr. B*, Vol. 696, pp. 329–336. A free reprint can be obtained by application to the publisher, Elsevier Science B.V., P.O. Box 330, 1000 AH Amsterdam, Netherlands.) The instructions can also be found on the Analytical Separation Home Page on the World Wide Web: access under <http://www.elsevier.nl/locate/chrom>

Journal of Chromatography has no page charges

Types of Contributions. The following types of papers are published: Regular research papers (full-length papers), Review articles, Short Communications, Discussions, Technical Notes, and Letters to the Editors. Short Communications are usually descriptions of short investigations, or they can report minor technical improvements of previously published procedures; they reflect the same quality of research as full-length papers, but should preferably not exceed five printed pages. Discussions (one or two pages) should explain, amplify, correct or otherwise comment substantively upon an article recently published in the journal. Technical Notes are descriptions of slight improvements of previously published methods and do not exceed four manuscript pages plus a maximum of two figures and tables. Letters to the Editor (max. two printed pages) bring up ideas, comments, opinions, experiences, advice, disagreements, insights, etc. For Review articles, see inside front cover under Submission of Papers.

Submission. Every paper must be accompanied by a letter from the senior author, stating that he/she is submitting the paper for publication in the *Journal of Chromatography B*.

Authors in Japan please note: Upon request, Elsevier Science Japan will provide authors with a list of people who can check and improve the English of their paper (*before submission*). Please contact our Tokyo office: Elsevier Science Japan, 1-9-15 Higashi-Azabu, Minato-ku, Tokyo 106; Tel. (03)-5561-5032, Fax (03)-5561-5045.

Manuscripts. Manuscripts should be typed in **double spacing** on consecutively numbered pages of uniform size. The manuscript should be preceded by a sheet of manuscript paper carrying the title of the paper and the name and full postal address of the person to whom the proofs are to be sent. As a rule, papers should be divided into sections, headed by a caption (e.g., Abstract, Introduction, Experimental, Results, Discussion, etc.) All illustrations, photographs, tables, etc., should be on separate sheets. **Electronic manuscripts:** Electronic manuscripts have the advantage that there is no need for the rekeying of text, thereby avoiding the possibility of introducing errors and resulting in reliable and fast delivery of proofs.

For the initial submission of manuscripts for consideration, hardcopies are sufficient. Upon revision, your disk and (**exactly matching**) printed version (printout, hardcopy) should be submitted together to the accepting editor or Editorial Office **according to their request**. Double density (DD) or high density (HD) diskettes (3 1/2 or 5 1/4 inch) are acceptable. It is important that the file saved is in the native format of the wordprocessor program used. Label the disk with the name of the computer and wordprocessing package used, your name, and the name of the file on the disk. Further information may be obtained from the Publisher.

Abstract. All articles should have an abstract of 50–100 words which clearly and briefly indicates what is new, different and significant. No references should be given.

Introduction. Every paper must have a concise introduction mentioning what has been done before on the topic described, and stating clearly what is new in the paper now submitted.

Experimental conditions should preferably be given on a *separate* sheet, headed "Conditions". These conditions will, if appropriate, be printed in a block, directly following the heading "Experimental".

Illustrations. The figures should be submitted in a form suitable for reproduction, drawn in Indian ink on drawing or tracing paper. Each illustration should have a caption, all the captions being typed (with double spacing) together on a *separate sheet*. If structures are given in the text, the original drawings should be provided. Coloured illustrations are reproduced at the author's expense. The written permission of the author and publisher must be obtained for the use of any figure already published. Its source must be indicated in the legend.

References. References should be numbered in the order in which they are cited in the text, and listed in numerical sequence on a separate sheet at the end of the article. Please check a recent issue for the layout of the reference list. Abbreviations for the titles of journals should follow the system used by *Chemical Abstracts*. Articles not yet published should be given as "in press" (journal should be specified), "submitted for publication" (journal should be specified), "in preparation" or "personal communication".

Vols. 1–651 of the *Journal of Chromatography*; *Journal of Chromatography, Biomedical Applications* and *Journal of Chromatography, Symposium Volumes* should be cited as *J. Chromatogr.* From Vol. 652 on, *Journal of Chromatography A* should be cited as *J. Chromatogr. A* and *Journal of Chromatography B* as *J. Chromatogr. B*.

Dispatch. Before sending the manuscript to the Editor please check that the envelope contains four copies of the paper complete with references, captions and figures. One of the sets of figures must be the originals suitable for direct reproduction. Please also ensure that permission to publish has been obtained from your institute.

Proofs. One set of proofs will be sent to the author to be carefully checked for printer's errors. Corrections must be restricted to instances in which the proof is at variance with the manuscript.

Reprints. Fifty reprints will be supplied free of charge. Additional reprints can be ordered by the authors. An order form containing price quotations will be sent to the authors.

For **Publication Schedule** see inside front cover.